

Applicant: Ron S. Israeli et al.,
Serial No: 08/403,803
Filed: March 17, 1995
Page 3

In the April 5, 2001 Notice To Comply, the Examiner stated that this application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). The Examiner stated that however, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reasons set forth in the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Disclosures. The Examiner stated that the nucleotide and/or amino acid disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reasons: The Examiner stated that neither the Brief Description of the Drawings section or the figures themselves for Figures 14-4 to 14-8 and 16-1 to 16-11 contain SEQ ID Nos. The Examiner stated that these sequences must have their own unique sequence identifiers or contains reference to a pre-existing SEQ ID NO. (e.g. amino acid residues 45-750 of SEQ ID NO:2). The Examiner stated that applicants need to provide a substitute computer readable for (CRF) copy of the "Sequence Listing", a substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification and a statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

In response, applicants submit a substitute paper copy of the Sequence Listing attached hereto as **Exhibit B** in compliance with the requirements of 37 C.F.R. §1.824. In addition applicants submit herewith a computer readable form (CRF) copy of the "Sequence Listing" as required by 37 C.F.R. §1.825(d). Further, applicants submit herewith as **Exhibit C** a statement in accordance

Applicant: Ron S. Israeli et al.,
Serial No: 08/403,803
Filed: March 17, 1995
Page 4



with 37 C.F.R. §1.821(f), certifying that the substitute computer readable form containing the nucleic acid and/or amino acid sequences as required by 37 C.F.R. §1.821(e) contains the same information which was submitted as the "Sequence Listing" attached as Exhibit B and contains no new matter.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorneys invites the Examiner to telephone either of them at the number provided below.

No fee, other than the enclosed \$195.00 fee for a two-month extension of time, is deemed necessary in connection with the filing of this Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

Two handwritten signatures, one above the other, in black ink.

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.
7-2-01
John P. White Date
Reg. No. 28,678
Spencer H. Schneider
Reg. No. 45,923

John P. White
Registration No. 28,678
Spencer H. Schneider
Registration No. 45,923
Attorneys for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400